<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/20/quest-diagnostics-inc-plans-quarterly-dividend-of-0-53-nysedgx.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-20T12:02:41+00:00"/>
    <meta property="og:title" content="Quest Diagnostics Inc Plans Quarterly Dividend of $0.53 (NYSE:DGX)"/>
    <meta property="og:description" content="Quest Diagnostics Inc (NYSE:DGX) declared a quarterly dividend on Wednesday, November 20th, RTT News reports. Investors of record on Tuesday, January 14th will be paid a dividend of 0.53 per share by the medical research company on Wednesday, January 29th. This represents a $2.12 dividend on an annualized basis and a yield of 2.03%. NYSE:DGX […]"/>
  </head>
  <body>
    <article>
      <h1>Quest Diagnostics Inc Plans Quarterly Dividend of $0.53 (NYSE:DGX)</h1>
      <address><time datetime="2019-11-20T12:02:41+00:00">20 Nov 2019, 12:02</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/dgx.jpg"/>
      </figure>
      <p><b>Quest Diagnostics Inc</b> (NYSE:DGX) declared a quarterly dividend on Wednesday, November 20th, <a href="https://www.rttnews.com/calendar/Dividend.aspx?PageNum=1">RTT News</a> reports. Investors of record on Tuesday, January 14th will be paid a dividend of 0.53 per share by the medical research company on Wednesday, January 29th. This represents a $2.12 dividend on an annualized basis and a yield of 2.03%.</p>
      <p><a href="https://www.marketbeat.com/stocks/NYSE/DGX/dividend/">NYSE:DGX</a> traded up $0.10 during trading hours on Wednesday, reaching $104.58. The company’s stock had a trading volume of 15,453 shares, compared to its average volume of 953,299. The company has a market capitalization of $14.04 billion, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 2.19 and a beta of 0.85. Quest Diagnostics has a 12 month low of $78.95 and a 12 month high of $107.97. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.83 and a current ratio of 0.88. The stock has a 50 day moving average price of $102.89 and a two-hundred day moving average price of $101.51.</p>
      <p>Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.71 by $0.05. The company had revenue of $1.96 billion during the quarter, compared to the consensus estimate of $1.94 billion. Quest Diagnostics had a net margin of 9.58% and a return on equity of 15.32%. Quest Diagnostics’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.68 earnings per share. As a group, analysts predict that Quest Diagnostics will post 6.49 EPS for the current fiscal year.</p>
      <p>In other news, CAO Michael J. Deppe sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $106.00, for a total transaction of $530,000.00. Following the transaction, the chief accounting officer now directly owns 28,671 shares of the company’s stock, valued at $3,039,126. The sale was disclosed in a legal filing with the SEC, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/1022079/000102207919000168/xslF345X03/wf-form4_156892493506700.xml">the SEC website</a>. Corporate insiders own 1.86% of the company’s stock.</p>
      <p>A number of equities analysts recently commented on the stock. Canaccord Genuity reissued a “buy” rating and issued a $113.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, October 23rd. Credit Suisse Group boosted their price objective on shares of Quest Diagnostics from $99.00 to $105.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. JPMorgan Chase &amp; Co. boosted their price objective on shares of Quest Diagnostics from $100.00 to $111.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. UBS Group reduced their price objective on shares of Quest Diagnostics from $103.00 to $102.00 and set a “neutral” rating for the company in a research note on Monday, October 21st. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> raised Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 price target on the stock in a research report on Monday, September 30th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $105.27.</p>
      <p>
        <b>About Quest Diagnostics</b>
      </p>
      <p>Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/the-four-types-of-profit-margin/">Limitations of analyzing profit margin</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/DividendChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/>
      </figure>
    </article>
  </body>
</html>